Should a 75-Year-Old Man Have a Prostate Biopsy?

Whether a 75-year-old man should have a prostate biopsy depends far more on his overall health and life expectancy than on the number 75 itself. Major guidelines have historically drawn a line near this age, and for good reason: prostate cancer typically takes years to become life-threatening, and the majority of men in their late seventies already carry slow-growing tumors that will never cause symptoms. But “75” is not a biological switch. A fit 75-year-old with a decade or more of expected life ahead and a worrisome PSA trend faces a genuinely different calculation than a 75-year-old managing heart failure and diabetes. The real question is not whether you are too old for a biopsy, but whether the information a biopsy provides would actually change what you or your doctor do next.

Why Age 75 Became the Cutoff

The U.S. Preventive Services Task Force issued a landmark recommendation stating that men aged 75 and older should not be screened for prostate cancer with PSA testing, grading it a “D” recommendation, meaning the harms were judged to outweigh the benefits.¹ That guidance was later softened for men aged 55 to 69, where the Task Force acknowledged a small net benefit of screening, but the skepticism about screening older men persisted. The reasoning was straightforward: prostate cancer grows slowly enough that treatment benefits typically take a decade or longer to materialize, and by 75, many men are statistically more likely to die of something else first.

This does not mean every professional organization agrees. The American Urological Association takes a more individualized stance, suggesting that men over 70 with good health and a long life expectancy can still benefit from shared decision-making about PSA testing and biopsy. The tension between these positions captures the central dilemma: guidelines written for populations do not always fit individual patients.

How Common Prostate Cancer Is at This Age

One of the most striking facts about prostate cancer is that it exists in the bodies of far more men than it ever harms. A systematic review of autopsy studies found that the average prevalence of incidental prostate cancer climbed from about 5% in men under 30 to roughly 59% in men over 79.² That figure means more than half of men who die of unrelated causes at that age already have cancer cells in their prostate without ever knowing it. A Japanese forensic autopsy study reported a lower absolute rate but the same age trend, with the highest prevalence among men in their eighties.³

This is the heart of the overdiagnosis problem. If you biopsy enough older men, you will find cancer in a large share of them, but most of those cancers would never have caused trouble. One modeling study estimated that if PSA testing had been limited to men under 60, about 85% of the excess prostate cancer diagnoses associated with PSA-era screening in the United States could have been avoided.⁴ Each of those “excess” diagnoses represents a man who got treated or monitored for a cancer that would never have harmed him, often at a real cost to his quality of life.

When the Biopsy Still Makes Sense

None of this means biopsy is never appropriate after 75. A Canadian study looking at biopsies in elderly men found that 53% were positive for cancer and 78% of those positives were clinically significant, meaning tumors that could progress and cause harm.⁵ In other words, when a urologist has a specific clinical reason to biopsy an older man, the odds of finding meaningful disease are not trivial. The issue is not whether prostate cancer exists at this age, because it almost certainly does, but whether the particular cancer found is aggressive enough to warrant intervention within the man’s expected lifespan.

Situations where biopsy at 75 becomes more defensible include a rapidly rising PSA, a suspicious finding on digital rectal exam, urinary symptoms that suggest locally advanced disease, or MRI imaging that flags a high-suspicion lesion. In these scenarios, the question shifts from “should we look?” to “we already have a reason to look, and the man is healthy enough that the answer would change management.”

Life Expectancy and Comorbidities Matter More Than Age

The single most important factor in this decision is not chronological age but estimated life expectancy, and that is driven largely by comorbid conditions. A large U.S. population-based study found that among men aged 75 and older at diagnosis with three or more comorbid conditions, the 10-year rate of dying from something other than prostate cancer was 71%.⁶ Even prostate cancer-specific mortality was only about 3% for low-risk disease and 7% for intermediate-risk disease across all comorbidity groups in that study. High-risk disease was meaningfully different, at about 18%, but even then, the odds of dying from something else were far higher for men carrying multiple health problems.

A separate study confirmed the pattern: each point increase on the Charlson comorbidity index roughly doubled the hazard of dying from a non-prostate-cancer cause, and men with scores of 3 or higher had more than eight times the hazard of non-prostate death compared with men with no comorbidities.⁷ Among low- and intermediate-risk prostate cancer patients, prostate cancer mortality was vanishingly rare regardless of comorbidity burden.

The practical takeaway: a 75-year-old man with no major health problems, who exercises regularly and has reasonable odds of living another 10 to 15 years, is in a different category from a 75-year-old managing heart disease, diabetes, and chronic lung disease. For the first man, finding and addressing an aggressive cancer could genuinely extend his life. For the second, the cancer diagnosis is more likely to add anxiety and side effects than years.

Frailty as a Separate Risk Factor

Recent research has added another layer to this decision: frailty. A study of a large privately insured cohort found that frailty was associated with complications after prostate biopsy independently of both age and comorbidity burden.⁸ The study’s mean patient age was only about 58, which underscores an important point: frailty is not just an old-person problem, and conversely, being 75 does not automatically make you frail. But in geriatric populations, frailty assessments can meaningfully predict who will tolerate a biopsy well and who faces elevated risks from even a routine procedure.

Geriatric oncology guidelines increasingly recommend formal frailty screening before making cancer-related decisions in older adults. Tools that evaluate walking speed, grip strength, weight loss, exhaustion, and activity level give a more honest picture of biological age than the date on a birth certificate.

Risks of the Biopsy Procedure Itself

Prostate biopsy is generally safe, but “generally safe” is not the same as risk-free, and the risk profile matters more in older or frailer men. The traditional approach, transrectal ultrasound-guided biopsy, carries an infection rate that has been climbing over the past decade, driven largely by antibiotic-resistant bacteria. In the European Randomized Study of Screening for Prostate Cancer, fever occurred in about 4% of transrectal biopsies and hospitalization in about 0.8%, with infections accounting for roughly 80% of those admissions.⁹ A Medicare-based analysis found that biopsy was associated with a roughly 2.65-fold increased risk of infection-related hospitalization within 30 days compared to controls.¹⁰

The transperineal approach, which goes through the skin between the scrotum and rectum rather than through the rectal wall, has gained ground partly because it carries a lower infection rate. A Middle Eastern center comparing the two approaches found infection rates of about 1.2% for transperineal versus 4.1% for transrectal biopsy.¹¹ For a 75-year-old weighing the decision, asking the urologist which route they plan to use and why is a reasonable conversation to have. Transperineal biopsy is increasingly the default at major centers, though availability varies.

Tools That Can Help You Avoid an Unnecessary Biopsy

A PSA level above 4 ng/mL used to trigger an almost automatic biopsy referral. That era is largely over, replaced by a layered approach that uses additional tests to separate men who truly need tissue sampling from those who can safely be monitored. If you are 75 and your doctor has flagged a rising PSA, several tools can help refine the picture before anyone puts a needle in your prostate.

Multiparametric MRI has become a front-line triage tool. A prospective study found that MRI had a sensitivity of 93% to 96% for clinically significant cancer, meaning it caught the vast majority of dangerous tumors.¹² When the MRI looks clean, the chances of missing a significant cancer are low, though not zero. Some researchers have cautioned that the negative predictive value of prostate MRI is in the range of 76% to 87%, which means a clean scan does not completely rule out significant disease.¹³ Still, combining MRI scoring with PSA density (the PSA level divided by the prostate volume measured on imaging) can further sharpen the decision. One study found that using PSA density alongside MRI results avoided biopsy in 63 per 1,000 men without missing clinically significant cancers.¹⁴

PSA density alone has shown value even without MRI. A study of men with elevated PSA but negative MRI found that PSA density was the strongest independent predictor of cancer on biopsy, outperforming both total PSA and the free-to-total PSA ratio.¹⁵

Beyond imaging, blood- and urine-based biomarkers now offer additional filtering. The Prostate Health Index (phi) and the 4Kscore are blood tests that outperform plain PSA for predicting whether a biopsy will find significant cancer.¹⁶ Urine-based tests like SelectMDx and ExoDx work on a similar principle. A validation study of contemporary biomarkers found that their use could spare roughly 15% to 50% of unnecessary biopsies while still catching 90% to 95% of clinically significant cancers.¹⁷ For a 75-year-old, these tools can be the difference between proceeding to biopsy and having enough reassurance to monitor safely.

The Upgrading Problem in Older Men

One complication specific to older men is that biopsies tend to underestimate how aggressive their cancers actually are. A systematic review and meta-analysis found that older age was associated with a significantly increased risk of Gleason score upgrading, meaning the cancer looked more dangerous on the surgical specimen than it had on the biopsy sample.¹⁸ Overall, upgrading occurred in about a third of patients going from biopsy to prostatectomy, and the risk rose with age. Pathological upstaging, where the cancer turns out to be more locally advanced than expected, also increased in older patients.

This cuts both ways for the 75-year-old. On one hand, it means a biopsy showing low-grade disease might be falsely reassuring. On the other hand, the man who was already unlikely to be offered surgery (because of age or comorbidities) may not benefit from knowing the precise grade if active treatment was never going to be the plan. The upgrading risk is most relevant for men on the fence between active surveillance and treatment, where it can tip the balance toward closer monitoring or intervention.

What Happens After a Positive Biopsy at 75

This is arguably the question that matters most, because a biopsy that leads to aggressive treatment in a man with limited life expectancy can do more harm than good. Prostate cancer treatment carries substantial long-term side effects. A study tracking outcomes over 12 years found that prostatectomy carried roughly a seven-fold increase in the hazard of urinary or sexual complications compared to no treatment, and radiotherapy carried about a three-fold increase.¹⁹ Erectile dysfunction, urinary incontinence, and urethral stricture were all dramatically more common after surgery. Radiotherapy had a somewhat better side-effect profile but still elevated the risk of erectile dysfunction about six-fold in the first two years.

For many older men, active surveillance or watchful waiting is the more appropriate path after a positive biopsy. Active surveillance involves regular PSA checks, periodic imaging, and sometimes repeat biopsies to monitor whether the cancer is progressing. Watchful waiting is even less intensive, deferring treatment unless symptoms develop. As one recent review put it, the risk of dying from untreated prostate cancer is limited in the first five to ten years after diagnosis, and the benefit of treatment accrues mainly in men with more than ten years of life expectancy.²⁰ For a 75-year-old with low- or intermediate-risk disease, monitoring without immediate treatment is often the most rational choice.

The Psychological Side of the Decision

Even setting aside the physical risks, the biopsy process itself carries a psychological cost that deserves honest discussion. Nearly half of men who undergo prostate biopsy report significant procedure-related distress, with rates higher among men whose results come back positive (about 59%) or indeterminate (about 54%).²¹ Men with a tendency to worry about their health had particularly elevated odds of distress, with high health anxiety associated with roughly a seven-fold increase.

Another study found that overall anxiety and depression levels were generally low and close to normal in the broader biopsy population, but spiked meaningfully among men who received a cancer diagnosis and among those experiencing problematic physical symptoms in the days after the procedure.²² The waiting period for results is its own source of strain: about 41% of men awaiting biopsy results experience clinical levels of psychological distress, with anxiety being the dominant feature.²³

For a man in his mid-seventies, the emotional weight of a prostate cancer diagnosis can be disproportionate to its medical significance. Being told “you have cancer” triggers a cascade of worry and decision-making even when the cancer is low-grade and unlikely to affect life span. If the likely management plan after diagnosis is monitoring rather than treatment, a man should weigh whether he wants to carry the psychological burden of a cancer label for what may be the remainder of his life. Some men feel empowered by knowing; others find the knowledge corrosive. There is no wrong answer, but the question deserves to be asked before the biopsy, not after.

Shared Decision-Making in Practice

Guidelines across the board now emphasize that prostate biopsy decisions in older men should involve shared decision-making, meaning a genuine conversation between patient and doctor rather than a unilateral recommendation. A review in Nature Reviews Urology examined how decision aids perform in this context and found that while the results on reducing decisional conflict were mixed, the tools consistently improved patient knowledge about the tradeoffs involved.²⁴ The ideal conversation covers what the PSA and any additional tests suggest, what the biopsy might find, what you would realistically do with the information, and what the alternatives to biopsy are.

Questions worth raising with your doctor include: What is my estimated life expectancy given my current health? If the biopsy finds cancer, would treatment be recommended, or would we monitor? Could MRI, biomarkers, or PSA density narrow the picture enough to defer biopsy safely? And if we do find cancer, how would knowing change my day-to-day life? If the honest answers suggest that treatment would not be offered regardless, or that the chance of meaningful cancer is low, the strongest move may be to skip the biopsy entirely and continue monitoring.

Racial Differences in Prostate Cancer Risk

The biopsy calculus shifts for Black men, who face both higher incidence and more aggressive prostate cancer at every age. A study of veterans found that Black men were 50% more likely than White men to be diagnosed with prostate cancer on their first biopsy after controlling for PSA and other factors. At a PSA of 4.0 ng/mL, a Black man had a 49% probability of cancer compared to 39% for a White man. Put another way, a Black man with a PSA of 4.0 carried roughly the same cancer risk as a White man with a PSA of 13.4.²⁵ These differences mean that the general population thresholds for when to biopsy and when to hold off may be too conservative for Black men. A 75-year-old Black man in good health with a modestly elevated PSA has a stronger case for pursuing biopsy than the population-level guidelines might suggest, and this should be factored into any shared decision-making conversation.

When Skipping the Biopsy Is the Right Call

There are clinical situations where the answer is fairly clear-cut. A man with multiple serious health conditions, limited mobility, and a life expectancy under five years is unlikely to benefit from finding prostate cancer, even if it is there. A mildly elevated PSA in the absence of symptoms, a suspicious exam, or concerning imaging is often best managed with periodic re-checks. And a man who has already decided he would not want surgery, radiation, or hormonal therapy under any circumstances may reasonably conclude that the information a biopsy provides has no actionable value for him.

Conversely, a healthy 75-year-old with a life expectancy over 10 years, a sharply rising PSA, or a high-suspicion MRI lesion still has real potential to benefit from diagnosis and, if necessary, targeted treatment or active surveillance with curative intent as a backup. The age on the chart should inform the conversation but should not end it.